Neuromyelitis Optica
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Enspryng (satralizumab) — Roche Registration GmbH
Authorised market approval of Enspryng (satralizumab) by Roche Registration GmbH for neuromyelitis optica in the European Union.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases [Phase 2]
Phase 2 clinical trial investigating autologous stem cell transplant for neurologic autoimmune diseases is currently active but not recruiti…
-
EMA approval · 2026-02-17EMA Authorised: Uplizna (inebilizumab) — Amgen Europe B.V.
The European Medicines Agency has authorised Uplizna (inebilizumab) for the treatment of Neuromyelitis Optica in adults.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
The longitudinal CONQUER study is a long-term clinical trial examining rare neuroimmunologic disorders, including Neuromyelitis Optica and r…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Biobank For MS And Other Demyelinating Diseases
Sponsor Accelerated Cure Project for Multiple Sclerosis reports an active biobank study for multiple sclerosis and related demyelinating dis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD [Phase 3]
Phase 3 trial update examining slow vs rapid glucocorticoid tapering in NMOSD patients treated with inebilizumab. The study is not yet recru…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica [Phase 1]
Phase 1 clinical trial evaluating the safety and efficacy of CAR-T cell therapy for relapsed/refractory Neuromyelitis Optica has completed. …
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
A clinical trial led by Icahn School of Medicine at Mount Sinai investigates longitudinal cortical demyelination in Multiple Sclerosis and r…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]
Clinical trial update notes safety and efficacy evaluation of daratumumab in patients with anti-AQP4 antibody positive neuromyelitis optica …
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2, Phase 3]
A pediatric Phase 2/3 trial of eculizumab for relapsing neuromyelitis optica spectrum disorder was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack [Phase 2]
Phase 2 clinical trial evaluating the FcRn antagonist efgartigimod for acute neuromyelitis optica spectrum disorder attacks is listed as not…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO [NA]
An in vitro study assesses the biological and immunological activity of Imotopes candidate compounds on blood cells from patients with stabi…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD [Phase 1, Phase 2]
A longitudinal Phase 1/2 trial evaluating ACTEMRA (tocilizumab) as monotherapy in highly active neuromyelitis optica spectrum disorders has …
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD [Phase 3]
Phase 3 trial of ravulizumab in adults with neuromyelitis optica spectrum disorder has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Neuromyelitis Optica (NMO) & Cetirizine [Phase 1, Phase 2]
A Phase 1/2 clinical trial investigating cetirizine for Neuromyelitis Optica has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2022-08-23Clinical Trial Update: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients [Phase 3]
Open-label extension of eculizumab in relapsing neuromyelitis optica shows continuing assessment in a Phase 3 study.
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) [Phase 3]
Phase 3 trial evaluating satralizumab as add-on therapy for neuromyelitis optica and NMOSD completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
A Phase 3 trial evaluated satralizumab as monotherapy for neuromyelitis optica and NMOSD, with completed status and results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-28Clinical Trial Update: A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) [Phase 4]
Pilot Phase 4 trial investigating mitoxantrone for recurrent neuromyelitis optica (Devic's disease) has completed.
-
CLINICAL_TRIALS trial_result · 2020-04-17Clinical Trial Update: Scrambler Trial for Pain in NMOSD [NA]
A completed NMOSD pain trial (Scrambler) with posted results.
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]
A completed Phase 2/3 clinical trial evaluating inebilizumab for Neuromyelitis Optica Spectrum Disorders.
-
CLINICAL_TRIALS withdrawal · 2019-11-20Clinical Trial Update: Autologous Transplant To End NMO Spectrum Disorder [Phase 2, Phase 3]
A clinical trial investigating autologous transplant for Neuromyelitis Optica spectrum disorders has been withdrawn at Phase 2/Phase 3.
-
CLINICAL_TRIALS trial_result · 2019-10-24Clinical Trial Update: Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]
A Phase 2/3 trial comparing tocilizumab to azathioprine in neuromyelitis optica spectrum disorders (NMOSD) has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) [Phase 3]
Phase 3 randomized trial of eculizumab in AQP4 antibody-positive neuromyelitis optica spectrum disorder was terminated; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses [Phase 1]
Phase 1 trial update evaluating ublituximab for relapses in neuromyelitis optica and related spectrum disorders; results posted after comple…